Clinical Oncology Next Generation Sequencing (NGS) Market key Insights Based On

Posted by Arslan on May 29th, 2019

Looking at the current market trends as well as the promising demand status of the “Clinical Oncology Next Generation Sequencing (NGS) Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application; assisting them to draw conclusions out of this intelligent research report.

This report focuses on the global Clinical Oncology Next Generation Sequencing (NGS) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Clinical Oncology Next Generation Sequencing (NGS) development in United States, Europe and China.

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
In 2017, the global Clinical Oncology Next Generation Sequencing (NGS) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics

Market segment by Type, the product can be split into
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis

Market segment by Application, split into
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (2013-2025)
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2013-2025)
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size
2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (2013-2025)
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Manufacturers
3.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Manufacturers (2013-2018)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.3 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product/Solution/Service
3.4 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.5 Mergers & Acquisitions, Expansion Plans